Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Joseph D, Zibrak"'
Autor:
Jason H. Maley, George A. Alba, John T. Barry, Matthew N. Bartels, Talya K. Fleming, Christina V. Oleson, Leslie Rydberg, Sarah Sampsel, Julie K. Silver, Sabrina Sipes, Monica Verduzco‐Gutierrez, Jamie Wood, Joseph D. Zibrak, Jonathan Whiteson
Publikováno v:
PM&R. 14:77-95
Autor:
Lisa H. Lancaster, Joao A. de Andrade, Joseph D. Zibrak, Maria L. Padilla, Carlo Albera, Steven D. Nathan, Marlies S. Wijsenbeek, John L. Stauffer, Klaus-Uwe Kirchgaessler, Ulrich Costabel
Publikováno v:
European Respiratory Review, Vol 26, Iss 146 (2017)
Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated that pirfenidone reduces lung function decline, decreases
Externí odkaz:
https://doaj.org/article/8b549e828dcc4d888d8b3d843dc3d963
Autor:
Joshua J. Mooney, Daniel A. Culver, Sachin Chaudhary, Murali Ramaswamy, Gregory P. Cosgrove, Alpa G. Desai, Sonye K. Danoff, Amy Case, Stephen Weight, Rodeo Abrencillo, Joseph D. Zibrak, Srihari Veeraraghavan, Barry S. Shea, Nitin Y. Bhatt, Maryl Kreider, Doug Moore, Mary Beth Scholand, Shelley L. Schmidt, Thomas H. Schaumberg, Christopher S. King, Borna Mehrad, Justin M. Oldham, Bridget A. Graney, Adrian Shifren, Christophe He, Nathan Sandbo, Nishant Gupta, Michael Marll, Daniel F. Dilling, Tracy Luckhardt, Mridu Gulati, Tristan J. Huie, Craig S. Glazer, Nevins W. Todd, Peter Lacamera, Hyun Koo Kim, Mohamed Saad, Pauline Bianchi, James R. McCormick, Mark Hamblin, Yolanda N. Mageto, Robert Matthew Kottman, Teng Moua, Anna J. Podolanczuk, Scott Matson, Divya Patel, David Roe, Mary E. Strek, Lisa Lancaster, Krishna Thavarajah, Paul J. Wolters, Joyce S. Lee, Sydney B. Montesi, Rafael L. Perez, Rebecca Bascom, Nabeel Hamzeh, Tessy K. Paul, Anoop M. Nambiar, Prema Menon
Publikováno v:
Chest. 159:1517-1530
Background Management of patients with interstitial lung disease (ILD) requires subspecialized, comprehensive, multidisciplinary care. The Pulmonary Fibrosis Foundation established the Care Center Network (CCN) in 2013 with identified criteria to bec
Publikováno v:
Expert Review of Respiratory Medicine. 15:175-181
Forced vital capacity (FVC) decline is predictive of mortality in patients with idiopathic pulmonary fibrosis (IPF) and has been used as a clinical trial endpoint to define disease progression. How to interpret FVC findings in an individual patient w
Autor:
Jason H, Maley, George A, Alba, John T, Barry, Matthew N, Bartels, Talya K, Fleming, Christina V, Oleson, Leslie, Rydberg, Sarah, Sampsel, Julie K, Silver, Sabrina, Sipes, Monica, Verduzco-Gutierrez, Jamie, Wood, Joseph D, Zibrak, Jonathan, Whiteson
Publikováno v:
PMR : the journal of injury, function, and rehabilitationREFERENCES. 14(1)
Autor:
Joseph D. Zibrak
Publikováno v:
Chest. 156:815-816
Autor:
Neil R. MacIntyre, R. Richardson, F. Stokes, David A. Lynch, Eric L. Eisenstein, J. Rochon, Marilyn K. Glassberg, D. Dahlgren, DA Lynch, David A. Zisman, P. J. Wolters, W. Tate, T. Gentry-Bumpass, Francis Cordova, K. Kinser, Craig S. Glazer, L. Brewster, Joao A. de Andrade, T. Perez, Gary M. Hunninghake, T. Haram, J. Estrom, Bethany B. Moore, Maria L. Padilla, J. Pesarchick, G. Rahimova, Thomas V. Colby, Kelli L. Cain, B. Schmetter, E. Yow, E. Calahan, J. A. Golden, M. L. Han, Kevin K. Brown, K. Hwang, J. Kaur, K. Meiras, James P. Utz, J.L. Myers, J. De Andrade, Naresh P. Patel, H. Y. Reynolds, Barry H. Gross, M. Stewart, R. Wehrmann, N. A. Ettinger, John S. Sundy, Danielle Antin-Ozerkis, Mark P. Steele, S. R. White, Ivan O. Rosas, Q. Yang, M. Schwarz, Jonas Román, Imre Noth, N. Sandbo, I. Garic, G. Berhanu, Maryl Kreider, Eric S. White, K. Baumann, M. Kallay, H. Reynolds, E. Lyda, Galen B. Toews, Margaret L. Snyder, Ella E. Kazerooni, Aditi Satti, G.J. Criner, Irene Swift, J. Winsor, Simon L.F. Walsh, P. Debrosse, C. Holm, Richard C. Becker, K. Huang, John E. Fitzgerald, H. R. Collard, Mitchell A. Olman, Wendi R. Mason, Tedryl Gentry-Bumpass, Andrew H. Limper, Sara B. Calvert, Gail Weinmann, T. E. King, R. J. Kaner, A. Eller, A. Demersky, Mary E. Strek, Steven A. Sahn, Susan Lubell, Jennifer Hayes, Mary Beth Scholand, K. West, C. Bair, Graham Jones, Rhonda Roberts, M. Vey, James E. Chapman, Paul Hofmann, K. Le, Daniel A. Culver, Harold R. Collard, James P. Kiley, V. Monroy, L. Sardin, Joseph D. Zibrak, A. Sharlow, N. O'Banner, T. Colby, T. Thomas, Victor J. Thannickal, S. Ditta, M. Ingham, K. Chan, A. Snydsman, R. Greer, A. Johnson, John A. Belperio, M. Han, Ganesh Raghu, Kevin R. Flaherty, C. Matti, D. Hill, Craig E. Daniels, Kevin J. Anstrom, S. Maleckar, P. Lopez, D. Whelan, Paul J. Wolters, Joseph P. Lynch, Marvin I. Schwarz, M. Wang, Linda Davidson-Ray, William Lawson, P. Berry-Bell, Aamer Chughtai, S. Merli, Jeffrey A. Golden, Joseph A. Lasky, D. K. Hogarth, J. Walker, Joao deAndrade, R. Anderson, S. Ramey, James E. Loyd, Jay H. Ryu, T. Nguyen, Rex Edwards, R. Kidd, Lake Morrison, P. Dignacco, R. Jeffrey, Lisa Lancaster, Robert J. Kaner, Robert C. Hyzy, K. Bandong, Dolly Kervitsky, J. McClelland, Fernando J. Martinez, E. Simonet, E. Kagan, C. Brown, J. Lynch, A. Meredith, R. Perez, X. Tian, M. Rossman, R. Beci
Publikováno v:
Chest. 148:1034-1042
BACKGROUND The National Heart, Lung, and Blood Institute-sponsored IPF Clinical Research Network (IPFnet) studies enrolled subjects with idiopathic pulmonary fibrosis (IPF) to evaluate drug therapies in treatment trials. An adjudication committee (AC
Autor:
Marlies S. Wijsenbeek, Joao A. de Andrade, Joseph D. Zibrak, Wendi R. Mason, Ute Petzinger, Ulrich Costabel, Lisa Lancaster, Maria Padilla, Steven D. Nathan, Carlo Albera, Klaus-Uwe Kirchgaessler, Frank Gilberg
Publikováno v:
Diffuse Parenchymal Lung Disease.
Background: Fatigue is often reported as an adverse event (AE) in patients (pts) with IPF treated with PFD but is also an important symptom of IPF. Objective: To compare fatigue in pts with IPF receiving PFD or placebo (PBO) in the Phase III CAPACITY
Autor:
Carlo Albera, Ulrich Costabel, Marlies S. Wijsenbeek, Joao A. de Andrade, Klaus-Uwe Kirchgaessler, Lisa Lancaster, John L. Stauffer, Steven D. Nathan, Joseph D. Zibrak, Maria L. Padilla
Publikováno v:
European Respiratory Review, Vol 26, Iss 146 (2017)
European Respiratory Review, 26(146):Unsp 170057. European Respiratory Society
European Respiratory Review, 26(146):Unsp 170057. European Respiratory Society
Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated that pirfenidone reduces lung function decline, decreases
Autor:
David Price, Joseph D. Zibrak
Publikováno v:
NPJ Primary Care Respiratory Medicine
Interstitial lung disease (ILD) describes a group of diseases that cause progressive scarring of the lung tissue through inflammation and fibrosis. The most common form of ILD is idiopathic pulmonary fibrosis, which has a poor prognosis. ILD is rare